Long term clinical outcome of chronic hepatitis C patients with sustained virological response to interferon monotherapy
Open Access
- 1 October 2004
- Vol. 53 (10) , 1504-1508
- https://doi.org/10.1136/gut.2003.038257
Abstract
Background: The key end point for treatment efficacy in chronic hepatitis C is absence of detectable virus at six months after treatment. However, the incidence of clinical events during long term follow up of patients with sustained virological response is still poorly documented and may differ between the Eastern and Western world. Aims: To assess clinical end points during long term follow up of European patients with a sustained virological response to interferon monotherapy. Methods: Meta-analysis of individual patient data from eight European protocolled follow up studies of interferon treatment for chronic hepatitis C. Results: A total of 286 sustained virological responders and 50 biochemical responders (detectable virus but normal alanine aminotransferase levels) were followed up for 59 months. Fifteen sustained virological responders (5.2%) had cirrhosis before treatment and 112 (39%) had genotype 1. The late virological relapse rate after five years of follow up was 4.7% (95% confidence interval (CI) 2.0–7.4) among sustained virological responders; all late relapses occurred within four years after treatment. Among sustained virological responders, the rate of decompensation after five years of follow up was 1.0% (95% CI 0.0–2.3) and none developed hepatocellular carcinoma (HCC). Survival was comparable with the general population, matched for age and sex, the standard mortality ratio being 1.4 (95% CI 0.3–2.5). Clinical outcome of patients with cirrhosis was similar to other sustained virological responders. For biochemical responders, the rates of development of decompensation and HCC during long term follow up were 9.1% (95% CI 0.5–17.7) and 7.1% (95% CI 0–15.0), respectively. Conclusions: Five year survival of European sustained virological responders was similar to the overall population, matched for age and sex. No HCCs were detected during long term follow up.Keywords
This publication has 31 references indexed in Scilit:
- Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: A meta-analysis of individual patient dataHepatology, 2004
- Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patientsAmerican Journal of Gastroenterology, 2002
- Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trialPublished by Elsevier ,2001
- Relation of Interferon Therapy and Hepatocellular Carcinoma in Patients with Chronic Hepatitis CAnnals of Internal Medicine, 1998
- Long-Term Histologic Improvement and Loss of Detectable Intrahepatic HCV RNA in Patients with Chronic Hepatitis C and Sustained Response to Interferon-α TherapyAnnals of Internal Medicine, 1997
- Two-year biochemical, virological, and histological follow-up in patients with chronic hepatitis C responding in a sustained fashion to interferon alfa-2b treatment.1995
- Long‐term histologic and viral changes in patients with chronic hepatitis C who responded to alpha interferonLiver International, 1994
- [Long-term follow-up of chronic hepatitis C after treatment with recombinant interferon alpha-2a].1994
- Hepatitis C virus markers in patients with long-term biochemical and histological remission of chronic hepatitisLiver International, 1994
- Long-term follow-up of patients with chronic hepatitis C treated with different doses of interferon-alpha 2b.1993